Romidepsin is a structurally unique, bicyclic class I HDAC inhibitor that has been approved for the treatment of (r/r) primary T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) since 2009 [62]. Here, HDAC9 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.